Group 1 - U.S. stocks experienced an upward trend, with the Nasdaq Composite increasing by over 100 points on Friday [1] - CoreWeave, Inc. (CRWV) saw a significant rise in shares, jumping 4.8% to $127.15 after Loop Capital initiated coverage with a Buy rating and set a price target of $165 [1] - Quantum Computing Inc. (QUBT) shares surged by 22.5% to $22.47, indicating strong market interest [3] Group 2 - WhiteFiber, Inc. (WYFI) gained 17.6% to $27.53, with Roth Capital analyst maintaining a Buy rating and raising the price target from $25 to $28 [3] - Serve Robotics Inc. (SERV) rose 17% to $15.09, reflecting positive investor sentiment [3] - Aquestive Therapeutics, Inc. (AQST) increased by 16.5% to $5.75 after receiving news from the FDA that an advisory committee meeting is not required for its product [3] Group 3 - PureTech Health plc (PRTC) gained 16.2% to $17.08, showing strong performance in the market [3] - NANO Nuclear Energy Inc. (NNE) rose 15.3% to $44.10, indicating robust investor confidence [3] - Newegg Commerce, Inc. (NEGG) jumped 15% to $53.51, reflecting a positive market reaction [3] Group 4 - Oklo Inc. (OKLO) gained 14.4% to $120.13, continuing a remarkable 60% rally over the past month [3] - NuScale Power Corporation (SMR) rose 12.6% to $42.99, indicating strong market interest [3] - Centrus Energy Corp. (LEU) gained 9.4% to $287.38, reflecting positive investor sentiment [3] Group 5 - Symbotic Inc. (SYM) shares rose 8.5% to $55.59, indicating strong market performance [3] - Rigetti Computing, Inc. (RGTI) gained 8.5% to $26.98 after being awarded a three-year $5.8 million contract from the Air Force Research Laboratory [3] - Barrick Mining Corporation (B) rose 7% to $32.17, with B of A Securities analyst maintaining a Neutral rating and raising the price target from $29 to $34 [3] Group 6 - FedEx Corporation (FDX) gained 2.4% to $231.98 after reporting better-than-expected first-quarter EPS and sales, leading multiple analysts to raise their price targets [3]

Core Viewpoint - The FDA has informed Aquestive Therapeutics that no advisory committee meeting is required for the NDA of Anaphylm, indicating the target action date remains January 31, 2026 [1][5][7]. Company Developments - Shares of Aquestive Therapeutics rose by 28.1% following the FDA announcement [2][7]. - The stock has increased by 42.2% year-to-date, outperforming the industry average increase of 11.7% [4]. - The NDA for Anaphylm was accepted by the FDA in June 2025, with the target action date set for January 31, 2026 [5][7]. - Anaphylm is being developed as a non-invasive oral epinephrine product for treating severe allergic reactions, including anaphylaxis [6][8]. Market Potential - If approved, Anaphylm would be the first non-invasive, orally delivered epinephrine product approved by the FDA for severe allergic reactions [6][8]. - The management believes Anaphylm offers greater convenience compared to traditional autoinjectors [7]. - The company has secured $160 million in financing to support the potential launch of Anaphylm in the U.S. in Q1 2026 [8].